News Summary

Life Biosciences, a longevity-focused startup based in Boston, has commenced its first human clinical trial for a drug aimed at reversing age-related sight loss. The drug, ER-100, is designed to rejuvenate cells in the optic nerve, potentially restoring vision in conditions like glaucoma and NAION. This marks the first cellular-rejuvenation therapy of its kind to receive FDA clearance for human trials. The study will involve around 18 adults over the next year to assess the drug’s safety and possible side effects. Cofounded by David Sinclair, a Harvard Medical School genetics professor, Life Biosciences is exploring the potential of ER-100 to reverse cellular aging and develop applications for other age-related diseases.